Analyst Ratings and Financial Health of AbbVie Inc. (ABBV)

Dermira Inc now has $1.01 billion valuation. The stock increased 0.83% or $0.33 during the last trading session, reaching $40.31. About 433,090 shares traded. Dermira Inc (NASDAQ:DERM) has declined 7.44% since November 14, 2016 and is downtrending. It has underperformed by 2.62% the S&P500.

Legal & General Group Plc boosted its stake in shares of AbbVie by 1.7% in the second quarter.

In other news, SVP Azita Saleki-Gerhardt sold 8,300 shares of AbbVie stock in a transaction on Monday, September 11th. Palisade Asset Management LLC now owns 68,311 shares of the company's stock worth $4,953,000 after buying an additional 10,381 shares in the last quarter.

A stock rating usually tells investors how well a stock's market value relates to what analysts think is a fair value for the stock, based on an independent evaluation of the company. Oracle Corporation (NYSE:ORCL) has risen 14.08% since November 14, 2016 and is uptrending. It has underperformed by 6.07% the S&P500.

Among 38 analysts covering Oracle (NYSE:ORCL), 28 have Buy rating, 0 Sell and 10 Hold. Therefore 89% are positive. The company now has an average rating of "Buy" and an average price target of $93.68. The company was maintained on Friday, July 14 by Jefferies. Cowen & Co initiated Dermira Inc (NASDAQ:DERM) on Wednesday, August 19 with "Outperform" rating. Piper Jaffray maintained the shares of ABBV in report on Thursday, September 28 with "Buy" rating. The firm has "Neutral" rating by Atlantic Securities given on Tuesday, July 19. As it upholds an amended rate with more EPSGR it is prone to be a good target. BidaskClub upgraded shares of AbbVie from a "buy" rating to a "strong-buy" rating in a research note on Saturday. Tiaa Cref Invest Ltd, a New York-based fund reported 6.88M shares. As per Thursday, November 9, the company rating was reinitiated by UBS.

Investors sentiment decreased to 1.39 in Q2 2017. Its up 0.01, from 0.99 in 2017Q1. 62 funds opened positions while 297 raised stakes. Creative Planning has 1,961 shares. The insider ALBAN CARLOS sold 45,800 shares worth $3.21M. Zuckerman Invest Group Ltd Liability Company reported 76,333 shares or 1.48% of all its holdings. Quantbot LP stated it has 5,837 shares. 767,408 were accumulated by Jana Limited Com. Mcdaniel Terry & holds 18,634 shares or 0.26% of its portfolio. It also upped Flex Ltd (NASDAQ:FLEX) stake by 6.68 million shares and now owns 38.16 million shares. Campbell Newman Asset Incorporated reported 0.33% stake. Teachers Retirement Systems Of The State Of Kentucky reported 29,608 shares.

AbbVie Inc.'s ROI is valued at 18.00% relatively measuring the profitability on the investment. Salient Cap Advsrs Lc holds 10,590 shares. Corporate insiders own 0.23% of the company's stock. Therefore 52% are positive. The firm has "Buy" rating given on Friday, September 15 by Jefferies. BMO Capital Markets released guidance on ABBV stating a rating of "Hold" and a price target of $66.00. The stock has "Buy" rating by Drexel Hamilton on Wednesday, June 21. As per Monday, October 16, the company rating was maintained by SunTrust. The stock has "Buy" rating by Jefferies on Monday, June 26. They set an "outperform" rating and a $95.00 price objective on the stock. The firm has "Hold" rating by Credit Suisse given on Wednesday, June 7. AbbVie presently has a consensus rating of "Buy" and an average target price of $93.68. The firm's revenue for the quarter was up 8.8% compared to the same quarter last year. sell-side analysts forecast that AbbVie will post 5.55 EPS for the current fiscal year. Days to cover decreased -1.0 to 2.0 and the percentage of shorted shares was 0.01% on October 31. ABBV's profit will be $2.28B for 16.31 P/E if the $1.43 EPS becomes a reality. The company reported $1.41 earnings per share for the quarter, topping analysts' consensus estimates of $1.39 by $0.02.

Since May 18, 2017, it had 0 insider purchases, and 3 sales for $13.46 million activity. The stock was sold at an average price of $94.69, for a total transaction of $2,427,188.77.

Among 21 analysts covering Abbvie Inc (NYSE:ABBV), 11 have Buy rating, 1 Sell and 9 Hold.

Shares of AbbVie (NYSE ABBV) traded down $0.31 during mid-day trading on Friday, reaching $95.12.

Investors sentiment increased to 1 in Q2 2017. Its up 0.20, from 1.68 in 2017Q1.

Several other institutional investors have also added to or reduced their stakes in the company. 138 funds opened positions while 500 raised stakes. 447,174 were reported by Texas Permanent School Fund. Wade G W And invested in 9,289 shares.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, October 27th. Overbrook Mgmt accumulated 44,667 shares. Td Asset Management Inc owns 717,742 shares valued at $63,779,000. Princeton Capital owns 19,246 shares for 0.88% of their portfolio. The figure tells us what earnings were generated from invested capital of AbbVie Inc. Walter And Keenan Fincl Consulting Com Mi Adv owns 34,366 shares for 1.25% of their portfolio. Fernwood Invest Mngmt Llc invested in 0.92% or 17,505 shares. Broderick Brian C has invested 0.75% of its portfolio in AbbVie Inc (NYSE:ABBV). Renaissance Ltd Liability reported 0.05% in Ball Corporation (NYSE:BLL). Grantham Mayo Van Otterloo And Limited Company holds 0.01% or 14,500 shares in its portfolio.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.